Form 4: Biodesix CCO's Stock Transactions Post-RSU Vesting

Biodesix Chief Commercial Officer Kieran O'Kane reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Kieran O'Kane, Chief Commercial Officer of Biodesix Inc. (BDSX), reported changes in his beneficial ownership of common stock.
• On January 15, 2026, 805 restricted stock units (RSUs) vested, converting into 805 shares of common stock.
• Following this vesting, O'Kane beneficially owned 8,167 shares of common stock.
• On January 16, 2026, 298 shares of common stock were sold at a weighted average price of $8.1493 per share to cover tax obligations related to the RSU vesting.
• The sale price ranged from $8.10 to $8.28 per share.
• After the sale, O'Kane's direct beneficial ownership of common stock was 7,869 shares.
• The remaining 1,609 restricted stock units are subject to a vesting schedule.
• All reported numbers have been adjusted to reflect a one-for-twenty reverse stock split effective September 15, 2025.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax-related share sales), which are neither inherently positive nor negative for the company's operational or financial performance.

Positives

• Vesting of 805 restricted stock units (RSUs) on January 15, 2026, indicating compensation realization for the Chief Commercial Officer.

Negatives

• Sale of 298 shares of common stock at a weighted average price of $8.1493 on January 16, 2026, to cover tax liabilities, reducing direct beneficial ownership.

Future Outlook

The remaining 1,609 restricted stock units are scheduled to vest in a series of four successive equal annual installments, measured from January 15, 2024, contingent on the reporting person's continued service with Biodesix.

Industry Context

This Form 4 details a routine insider transaction related to executive compensation and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a routine, pre-scheduled insider transaction for compensation purposes. The sale of shares is small relative to the company's total outstanding shares.
• Employees: No direct impact on general employees.

Next Steps

• Future vesting of the remaining 1,609 restricted stock units in successive equal annual installments from January 15, 2024.

Key Dates

Keywords

Biodesix, BDSX, Kieran O'Kane, Chief Commercial Officer, CCO, insider trading, Form 4, SEC filing, stock transaction, RSU vesting, common stock, beneficial ownership, reverse stock split